Ligand | KiValue | ANOVA | Tukey | ||||
---|---|---|---|---|---|---|---|
MOR-1 | MOR-1C | MOR-1D | MOR-1E | MOR | p | ||
nM | |||||||
Morphine | 5.3 ± 2.0 | 2.4 ± 0.6 | 1.5 ± 0.2 | 2.3 ± 0.4 | <.05 | 1 vs 1D: | <.05 |
M6G | 5.2 ± 1.8 | 4.1 ± 1.2 | 4.8 ± 0.8 | 5.6 ± 0.7 | N.S. | ||
DAMGO | 1.8 ± 0.5 | 0.93 ± 0.19 | 0.71 ± 0.11 | 1.2 ± 0.5 | N.S. | ||
DADLE | 2.1 ± 0.3 | 3.2 ± 1.9 | 1.3 ± 0.4 | 2.5 ± 0.7 | N.S. | ||
DSLET | 12.5 ± 3.6 | 8.1 ± 1.2 | 3.6 ± 0.6 | 6.7 ± 1.4 | <.05 | 1 vs 1D: | <.05 |
Naloxone | 4.3 ± 0.9 | 2.8 ± 0.8 | 0.92 ± 0.08 | 2.8 ± 1.4 | N.S. | ||
Endomorphin 1 | 2.1 ± 0.8 | 1.4 ± 0.4 | 1.8 ± 0.3 | 2.4 ± 0.1 | N.S. | ||
Endomorphin 2 | 4.2 ± 1.8 | 1.6 ± 0.2 | 2.0 ± 0.3 | 4.4 ± 0.8 | N.S. | ||
β-Endorphin | 10.8 ± 2.9 | 5.8 ± 0.5 | 1.7 ± 0.4 | 5.0 ± 1.2 | <.0003 | 1 vs 1D: | <.001 |
1 vs 1E: | <.05 | ||||||
Dynorphin A | 10.9 ± 0.5 | 5.6 ± 0.8 | 2.2 ± 0.8 | 8.9 ± 1.1 | <.0001 | 1 vs 1C: | <.05 |
1 vs 1D: | <.001 | ||||||
1C vs 1E: | <.05 | ||||||
1D vs 1E: | <.001 | ||||||
U50,488H | >1000 | >1000 | >1000 | >1000 | |||
DPDPE | >1000 | >1000 | >1000 | >1000 |
[3H]DAMGO binding was performed in stable transfectants containing the indicated cDNAs. ANOVA was performed to determine whether there were differences among the various clones for each competitor, followed by Tukey’s post hoc analysis. Competition studies were performed using at least three concentrations of the indicated competitor. Results are the mean ± S.E. of at least three independent determinations.
DADLE, [d-Ala2,d-Leu5]-enkephalin; DSLET, [d-Ser2, Leu5]-enkephalin-Thr; DPDPE, [d-Pen2,d-Pen5]-enkephalin.